Effects of ethyl pyruvate on cardiac function recovery and apoptosis reduction after global cold ischemia and reperfusion Corrigendum in /10.3892/etm.2015.2951

Guo,Jialong; Zhang,Jun; Luo,Xiangyu; Luo,Weimin; Lin,Chengyi; Zhang,Kailun; Ji,Yanmei

doi:10.3892/etm.2014.1581

Effects of ethyl pyruvate on cardiac function recovery and apoptosis reduction after global cold ischemia and reperfusion

Corrigendum in: /10.3892/etm.2015.2951

Authors:
- Jialong Guo
- Jun Zhang
- Xiangyu Luo
- Weimin Luo
- Chengyi Lin
- Kailun Zhang
- Yanmei Ji
View Affiliations

Affiliations: Department of Cardiothoracic Surgery, Taihe Hospital Affiliated to Hubei Medical College, Shiyan, Hubei 442000, P.R. China, Department of Cardiovascular Surgery, Union Hospital, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China
Published online on: February 24, 2014 https://doi.org/10.3892/etm.2014.1581
Pages: 1197-1202

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study used an in vitro model of cold cardioplegia in isolated working rat hearts to evaluate the possible role of ethyl pyruvate (EP) in promoting cardiac function and preventing apoptosis. Two groups of rats were evaluated; the EP (2 mM EP; n=8) and control (n=8) groups. Isolated rat hearts were perfused with Krebs‑Henseleit buffer (KHB) for 30 min, arrested with cardioplegic solution and stored for 4 h in B21 solution at 4˚C. The hearts were reperfused with KHB for 45 min. EP was added to the cardioplegic and storage solutions and also to KHB for reperfusion. Cardiac parameters of the heart rate, including left ventricular systolic pressure, left ventricular end-diastolic pressure, left ventricular developed pressure and maximal rise rate of the left ventricular pressure, were monitored. In addition, coronary flow, adenosine triphosphate (ATP) levels and malondialdehyde (MDA) content were recorded and apoptotic cell determination was detected. The functional parameters in the EP group were significantly higher compared with those in the control group during the reperfusion period (P<0.05). In addition, ATP levels were higher in the EP group than in the control group and the content of MDA was lower in the EP group than in the control group. A concentration of 2 mM EP significantly reduced the number of apoptotic cells in the EP group compared with that of the control group (P<0.05). Therefore, EP significantly preserved cardiac function, enhanced tissue ATP levels, attenuated myocardial oxidative injury and markedly reduced apoptosis following myocardial ischemia in an in vitro model of 4 h of cold cardioplegia and reperfusion.

View Figures

View References

1	Stringham JC, Southard JH, Hegge J, Triemstra L, Fields BL and Belzer FO: Limitations of heart preservation by cold storage. Transplantation. 53:287–294. 1992. View Article : Google Scholar : PubMed/NCBI
2	Frank A, Bonney M, Bonney S, et al: Myocardial ischemia reperfusion injury: from basic science to clinical bedside. Semin Cardiothorac Vasc Anesth. 16:123–132. 2012. View Article : Google Scholar : PubMed/NCBI
3	Jang IS, Park MY, Shin IW, Sohn JT, Lee HK and Chung YK: Ethyl pyruvate has anti-inflammatory and delayed myocardial protective effects after regional ischemia/reperfusion injury. Yonsei Med J. 51:838–844. 2010. View Article : Google Scholar : PubMed/NCBI
4	Guo J, Zhang K, Ji Y, et al: Effects of ethyl pyruvate on myocardial apoptosis and expression of Bcl-2 and Bax proteins after ischemia-reperfusion in rats. J Huazhong Univ Sci Technolog Med Sci. 28:281–283. 2008. View Article : Google Scholar : PubMed/NCBI
5	Hu X, Cui B, Zhou X, et al: Ethyl pyruvate reduces myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein in rats. Mol Biol Rep. 39:227–231. 2012. View Article : Google Scholar : PubMed/NCBI
6	Jahania MS, Sanchez JA, Narayan P, Lasley RD and Mentzer RM Jr: Heart preservation for transplantation: principles and strategies. Ann Thorac Surg. 68:1983–1987. 1999. View Article : Google Scholar : PubMed/NCBI
7	DeBoer LW, Bekx PA, Han L and Steinke L: Pyruvate enhances recovery of rat hearts after ischemia and reperfusion by preventing free radical generation. Am J Physiol. 265:H1571–H1576. 1993.PubMed/NCBI
8	Manthorpe M, Cornefert-Jensen F, Hartikka J, Felgner J, Rundell A, Margalith M and Dwarki V: Gene therapy by intramuscular injection of plasmid DNA: studies on firefly luciferase gene expression in mice. Hum Gene Ther. 4:419–431. 1993. View Article : Google Scholar : PubMed/NCBI
9	Stanley PE: Extraction of adenosine triphosphate from microbial and somatic cells. Methods Enzymol. 133:14–22. 1986. View Article : Google Scholar : PubMed/NCBI
10	Yagi K: A simple fluorometric assay for lipoperoxide in blood plasma. Biochem Med. 15:212–216. 1976. View Article : Google Scholar : PubMed/NCBI
11	Ochiai K, Zhang J, Gong G, Zhang Y, Liu J, Ye Y, Wu X, Liu H, Murakami Y, Bache RJ, Ugurbil K and From AH: Effects of augmented delivery of pyruvate on myocardial high-energy phosphate metabolism at high workstate. Am J Physiol Heart Circ Physiol. 281:H1823–H1832. 2001.PubMed/NCBI
12	Mallet RT: Pyruvate: metabolic protector of cardiac performance. Proc Soc Exp Biol Med. 223:136–148. 2000. View Article : Google Scholar : PubMed/NCBI
13	Olivencia-Yurvati AH, Blair JL, Baig M and Mallet RT: Pyruvate-enhanced cardioprotection during surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 17:715–720. 2003. View Article : Google Scholar : PubMed/NCBI
14	Fink MP: Ethyl pyruvate: a novel anti-inflammatory agent. J Intern Med. 261:349–362. 2007. View Article : Google Scholar : PubMed/NCBI
15	Mallet RT, Sun J, Knott EM, Sharma AB and Olivencia-Yurvati AH: Metabolic cardioprotection by pyruvate: recent progress. Exp Biol Med (Maywood). 230:435–443. 2005.PubMed/NCBI
16	Aneja R and Fink MP: Promising therapeutic agents for sepsis. Trends Microbiol. 15:31–37. 2007. View Article : Google Scholar : PubMed/NCBI
17	Cruz RJ Jr, Harada T, Sasatomi E and Fink MP: Effects of ethyl pyruvate and other α-keto carboxylic acid derivatives in a rat model of multivisceral ischemia and reperfusion. J Surg Res. 165:151–157. 2011.
18	Wang Y, Li B, Li Z, Huang S, Wang J and Sun R: Improvement of hypoxia-ischemia-induced white matter injury in immature rat brain by ethyl pyruvate. Neurochem Res. 38:742–752. 2013. View Article : Google Scholar : PubMed/NCBI
19	Kung CW, Lee YM, Cheng PY, Peng YJ and Yen MH: Ethyl pyruvate reduces acute lung injury via regulation of iNOS and HO-1 expression in endotoxemic rats. J Surg Res. 167:323–331. 2011. View Article : Google Scholar : PubMed/NCBI
20	Akkoc H, Kelle I, Tunik S, Bahceci S, Sencar L, Ayaz E, Nergiz Y, Erdinc L and Erdinc M: Protective effect of ethyl pyruvate on liver injury in streptozotocin-induced diabetic rats. Acta Gastroenterol Belg. 75:336–341. 2012.PubMed/NCBI
21	Han Y, Englert JA, Yang R, Delude RL and Fink MP: Ethyl pyruvate inhibits nuclear factor-kappaB-dependent signaling by directly targeting p65. J Pharmacol Exp Ther. 312:1097–1105. 2005. View Article : Google Scholar
22	Uchiyama T, Delude RL and Fink MP: Dose-dependent effects of ethyl pyruvate in mice subjected to mesenteric ischemia and reperfusion. Intensive Care Med. 29:2050–2058. 1992. View Article : Google Scholar : PubMed/NCBI
23	Raedschelders K, Ansley DM and Chen DD: The cellular and molecular origin of reactive oxygen species generation during myocardial ischemia and reperfusion. Pharmacol Ther. 133:230–255. 2012. View Article : Google Scholar : PubMed/NCBI
24	Kao KK and Fink MP: The biochemical basis for the anti-inflammatory and cytoprotective actions of ethyl pyruvate and related compounds. Biochem Pharmacol. 80:151–159. 2010. View Article : Google Scholar : PubMed/NCBI
25	Fink MP: Ethyl pyruvate. Curr Opin Anaesthesiol. 21:160–167. 2008. View Article : Google Scholar
26	Sinha K, Das J, Pal PB and Sil PC: Oxidative stress: the mitochondria-dependent and mitochondria-independent pathways of apoptosis. Arch Toxicol. 87:1157–1180. 2013. View Article : Google Scholar : PubMed/NCBI
27	Handy DE and Loscalzo J: Redox regulation of mitochondrial function. Antioxid Redox Signal. 16:1323–1367. 2012. View Article : Google Scholar : PubMed/NCBI
28	Frank A, Bonney M, Bonney S, Weitzel L, Koeppen M and Eckle T: Myocardial ischemia reperfusion injury: from basic science to clinical bedside. Semin Cardiothorac Vasc Anesth. 16:123–132. 2012. View Article : Google Scholar : PubMed/NCBI
29	Dobsák P, Siegelova J, Wolf JE, Rochette L, Eicher JC, Vasku J, Kuchtickova S and Horky M: Prevention of apoptosis by deferoxamine during 4 hours of cold cardioplegia and reperfusion: in vitro study of isolated working rat heart model. Pathophysiology. 9:272002.PubMed/NCBI
30	Yue TL, Ma XL, Wang X, Romanic AM, Liu GL, Louden C, Gu JL, Kumar S, Poste G, Ruffolo RR Jr and Feuerstein GZ: Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol. Circ Res. 82:166–74. 1998. View Article : Google Scholar
31	Martin BJ, Valdivia HH, Bünger R, Lasley RD and Mentzer RM Jr: Pyruvate augments calcium transients and cell shortening in rat ventricular myocytes. Am J Physiol. 274:H8–H17. 1998.PubMed/NCBI